TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Financial Statements
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported trailing twelve-month revenue of $17.3B (up 4.1% year on year) and net income of $706.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.3B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TEVATEVA PHARMACEUTICAL INDUSTRIES LTDFollow TEVA — free
—
Price chart with a free account
- Market cap
- 45.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.12 | 16.12 | 18.31 | 20.32 | 20.31 | 18.27 | 16.89 | 16.66 | 15.88 | 14.93 | 15.85 | 16.54 | 17.26 | 17.32 | |
| Gross profit | 7.37 | 9.07 | 9.52 | 10.65 | 10.71 | 8.30 | 7.54 | 7.73 | 7.59 | 6.97 | 7.65 | 8.06 | 8.94 | 9.09 | |
| Research & development | 0.83 | 0.95 | 1.10 | 1.36 | 0.01 | 1.21 | 1.01 | 1.00 | 0.97 | 0.10 | 0.95 | 1.00 | 1.01 | 1.72 | |
| Operating income | 2.41 | 3.87 | 3.11 | 2.21 | 1.65 | -1.64 | -0.44 | -3.57 | 1.72 | -2.20 | 0.43 | -0.30 | 2.16 | 1.60 | |
| Pre-tax income | 2.20 | 3.65 | 2.96 | 1.82 | 1.25 | -2.60 | -1.27 | -4.41 | 0.66 | -3.16 | -0.62 | -1.28 | 1.22 | 0.71 | |
| Income tax | 0.17 | 0.28 | 0.13 | -0.14 | -0.04 | -0.20 | -0.28 | -0.17 | 0.21 | -0.64 | -0.01 | 0.68 | -0.18 | 0.01 | |
| Net income | 2.00 | 3.33 | 2.76 | 1.96 | 1.27 | -2.15 | -1.00 | -3.99 | 0.42 | -2.45 | -0.56 | -1.64 | 1.41 | 0.71 | |
| Diluted EPS ($) | 2.23 | 3.67 | 3.09 | 2.25 | 1.49 | -2.35 | -0.91 | -3.64 | 0.38 | -2.20 | -0.50 | -1.45 | 1.21 | 0.60 | |
| Diluted shares (bn) | 0.896 | 0.921 | 0.893 | 0.873 | 0.850 | 1.021 | 1.091 | 1.095 | 1.107 | 1.110 | 1.119 | 1.131 | 1.163 | — |
USD billions · SEC XBRL
TEVA PHARMACEUTICAL INDUSTRIES LTD — questions
- What is TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue?
- $17.3B over the twelve months to 2026-06-30, up 4.1% year on year, from its 10-Q and 10-K filings.
- What is TEVA PHARMACEUTICAL INDUSTRIES LTD's net income?
- $706.0M over the twelve months to 2026-06-30.
- What is TEVA PHARMACEUTICAL INDUSTRIES LTD's free cash flow?
- $1.3B over the twelve months to 2026-06-30.
- What are TEVA PHARMACEUTICAL INDUSTRIES LTD's diluted earnings per share?
- $0.60 over the twelve months to 2026-06-30.
Every figure on this page comes from TEVA PHARMACEUTICAL INDUSTRIES LTD's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.